Piramal Pharma to stay away from prescription business in India: Nandini Piramal

Piramal Pharma is not planning to re-enter the domestic prescription formulations business, according to chairperson Nandini Piramal. Instead, the company will focus on its consumer healthcare business, potentially acquiring OTC portfolios or brands, and explore targets in its global complex hospital generics business. Piramal Pharma will continue organic expansion in its CDMO business with a capex of $100-125 million.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gYsHVpO
via IFTTT